✨ Free AI Report
Immune-Onc Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Immune-Onc Therapeutics, Inc.
Company Research

Immune-Onc Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patie...

Analyst-debate audio for Immune-Onc Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Immune-Onc Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Early-stage myeloid checkpoint inhibitor developer with strong science backing and strategic partnerships, but execution and...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Immune-Onc Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Immune-Onc Therapeutics, Inc. Overview

Pro stress-test →

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patients. Founded in 2016 and headquartered in Palo Alto, the company focuses on first-in-class myeloid checkpoint inhibitors with a differentiated approach to cancer immunotherapy.

Strategic Profile

Pro stress-test →

The company has a focused pipeline targeting Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB) myeloid checkpoints, with lead programs IO-108 and IO-202 advancing through clinical trials. Immune-Onc has secured strategic partnerships with leading biopharmaceutical companies including BeiGene and Regeneron, and maintains research collaborations with top-tier institutions including Memorial Sloan Kettering Cancer Center.

Competitive Landscape

Pro stress-test →

Immune-Onc competes in the immuno-oncology space alongside companies developing checkpoint inhibitors and cellular immunotherapies. Direct competitors include Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma. However, the company's specific focus on LILRB myeloid checkpoints differentiates it from the broader PD-1/PD-L1 checkpoint inhibitor market dominated by larger pharmaceutical companies.

Industry Context

Immune-Onc Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2016 · Headquarters: Palo Alto, US · Employees: 13

What the analysts stress-tested

The top findings that survived the multi-agent debate for Immune-Onc Therapeutics, Inc..

  • Lead candidate IO-108 began a global Phase 1b/2 trial (January 2026) in solid tumors, advancing from completed Phase 1 monotherapy data
  • Focused pipeline targeting underexploited LILRB myeloid checkpoints, a validated but less crowded segment than PD-1/PD-L1 checkpoint space
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026IO-108 advanced to Phase 1b/2 global trial in advanced solid tumors and combination studies with anti-PD-1 agents
  • January 2023Completed $131M Series B extension financing to advance IO-108 and IO-202 development
Get alerted when Immune-Onc Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Arcus BiosciencesImmuno-oncology company developing checkpoint inhibitors and antibodies→Jounce TherapeuticsImmuno-oncology company targeting checkpoint molecules and myeloid modulation→Cstone PharmaceuticalsClinical-stage biotech developing myeloid checkpoint inhibitors in immuno-oncology→Tmunity TherapeuticsImmuno-oncology company developing checkpoint inhibitor therapeutics→

Compare Immune-Onc Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Immune-Onc Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Immune-Onc Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Immune-Onc Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Immune-Onc Therapeutics, Inc. do this quarter?”
“Is Immune-Onc Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Immune-Onc Therapeutics, Inc. do?+
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patie...
What is Immune-Onc Therapeutics, Inc.'s Cyborg Score?+
Immune-Onc Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Immune-Onc Therapeutics, Inc.'s main competitors?+
Named competitors include Arcus Biosciences, Jounce Therapeutics, Cstone Pharmaceuticals, Tmunity Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Immune-Onc Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Immune-Onc Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Immune-Onc Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.